WO2026104866 - PHARMACEUTICAL COMPOSITION COMPRISING 4-(4-((4-AMINOBUTAN-2YL)OXY)-2,6-DIBROMOPHENOXY)-2-ISOPROPYLPHENOL FOR MUSCLE PROTECTION IN MICROGRAVITY, HYPOXIA AND AGING
National phase entry is expected:
Publication Number
WO/2026/104866
Publication Date
21.05.2026
International Application No.
PCT/GR2025/050033
International Filing Date
29.10.2025
Title **
[English]
PHARMACEUTICAL COMPOSITION COMPRISING 4-(4-((4-AMINOBUTAN-2YL)OXY)-2,6-DIBROMOPHENOXY)-2-ISOPROPYLPHENOL FOR MUSCLE PROTECTION IN MICROGRAVITY, HYPOXIA AND AGING
[French]
COMPOSITION PHARMACEUTIQUE COMPRENANT DU 4-(4-[(4-AMINOBUTAN-2YL)OXY]-2,6-DIBROMOPHÉNOXY)-2-ISOPROPYLPHÉNOL POUR PROTECTION MUSCULAIRE EN MICROGRAVITÉ, HYPOXIE ET VIEILLISSEMENT
Applicants **
GRAVITY THERAPEUTICS P.C.
Inventors
MOUROUZIS, Iordanis
PANTOS, Constantinos
Priority Data
20240100816
18.11.2024
GR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2673 | |
| EPO | Filing, Examination, Granting | 12960 | |
| Japan | Filing, Examination, Granting | 2339 | |
| South Korea | Filing, Examination, Granting | 2442 | |
| USA | Filing, Examination, Granting | 8540 |
Total:
28,954
Contact Us
Abstract[English]
The present invention is related to a composition comprising a novel chemical compound with the chemical Name "4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol" and its use. The 4-(4-((4-Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2- isopropylphenol and related compounds are useful for treating microgravity induced damage such as skeletal muscle atrophy and dysfunction as well as cardiac dysfunction and are also useful for human diseases and conditions accompanied by significant loss of muscle mass and reduced endurance capacity, such as immobilized patients, cancer, heart failure, sepsis, diabetes mellitus, muscle genetic diseases and neurodegenerative disorders. In addition, 4-(4-((4- Aminobutan-2yl)oxy)-2,6-dibromophenoxy)-2-isopropylphenol and related compounds are useful for treating human diseases related to muscle degeneration and ageing such as sarcopenia and heart failure.[French]
La présente invention concerne une composition comprenant un nouveau composé chimique dont le nom chimique est « 4-(4-[(4-Aminobutan-2yl)oxy]-2,6-dibromophénoxy)-2- isopropylphénol » et son utilisation. Le 4-(4-[(4-Aminobutan-2yl)oxy]-2,6-dibromophénoxy)-2- isopropylphénol et des composés apparentés sont utiles pour traiter les dommages induits par la microgravité, telle qu'une atrophie et un dysfonctionnement des muscles squelettiques ainsi que le dysfonctionnement cardiaque, et sont également utiles pour traiter les maladies humaines et les états accompagnés d'une perte importante de la masse musculaire et d'une capacité d'endurance réduite, tels que les patients immobilisés, les patients atteints de cancer, d'insuffisance cardiaque, de septicémie, de diabète sucré, de maladies génétiques musculaires et de troubles neurodégénératifs. En outre, le 4-(4-[(4- Aminobutan-2yl)oxy]-2,6-dibromophénoxy)-2-isopropylphénol et les composés apparentés sont utiles pour traiter les maladies humaines liées à la dégénérescence musculaire et au vieillissement, telles que la sarcopénie et l'insuffisance cardiaque.